Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP)

Riechelmann, Rachel; Srimuninnimit, Vichien; Bordonaro, Roberto; Kavan, Petr; Di Bartolomeo, Maria; Maiello, Evaristo; ÇİÇİN, İRFAN; Garcia-Alfonso, Pilar; Chau, Ian; Fedyanin, Mikhail; Fernandez Martos, Carlos; Ter-Ovanesov, Mikhail; Peeters, Marc; Ko, Yoo-Joung; YALÇIN, ŞUAYİB; Karthaus, Meinolf; Aparicio, Jorge; Heinemann, Volker; Picard, Pascaline; Bury, Denise; Drea, Edward; Sobrero, Alberto

doi:10.1016/j.clcc.2019.05.003

Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP)

Atıf İçin Kopyala

Riechelmann R. P., Srimuninnimit V., Bordonaro R., Kavan P., Di Bartolomeo M., Maiello E., ...Daha Fazla

CLINICAL COLORECTAL CANCER, cilt.18, sa.3, ss.183-194, 2019 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 18 Sayı: 3
Basım Tarihi: 2019
Doi Numarası: 10.1016/j.clcc.2019.05.003
Dergi Adı: CLINICAL COLORECTAL CANCER
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.183-194
Hacettepe Üniversitesi Adresli: Evet

Özet

This study evaluated safety and quality of life in patients with metastatic colorectal cancer undergoing treatment with aflibercept and FOLFIRI (fluorouracil, leucovorin, irinotecan). Most patients treated with this combination experienced either improvement or stability in quality of life scores. Aflibercept plus FOLFIRI is tolerable in the treatment of patients with metastatic colorectal cancer with a safety profile similar to that seen in previous studies of these individual medications.